Dr. Boris SepesiAssociate Professor of Thoracic Surgery at the University of Texas
Dr. Boris Sepesi is an innovative thoracic surgeon and associate professor at the University of Texas MD Anderson Cancer Center in Houston, where he treats patients with pleural mesothelioma.
Get to Know Dr. Boris Sepesi
Surgical oncologist Dr. Boris Sepesi utilizes endoscopic, minimally invasive and traditional surgical techniques to treat patients with complex thoracic malignancies such as mesothelioma at the MD Anderson Cancer Center in Houston.
Sepesi handles cases of pleural mesothelioma, lung cancer, esophageal cancer and chest wall tumors as part of a multidisciplinary, personalized approach to treatment.
As an associate professor in the Department of Thoracic and Cardiovascular Surgery at the University of Texas, he also focuses on translational research, especially clinical trials involving promising new therapies for his patients.
Sepesi was a co-author of the latest study that retrospectively compared and contrasted different and aggressive surgeries used for pleural mesothelioma cancer at MD Anderson for the past 20 years.
He works closely now with Dr. Anne Tsao and Dr. David Rice in the specialized mesothelioma program at MD Anderson Cancer Center, which has been ranked the No. 1 adult cancer hospital in America for five consecutive years.
Specialties of Dr. Boris Sepesi
- Pleural mesothelioma
- Lung cancer
- Esophageal cancer
- Minimally invasive surgery
- Chest wall tumors
- Clinical trials
Dr. Boris Sepesi’s Experience and Education
- University of Texas MD Anderson Cancer Center
- University of Rochester Medical Center (Residency and fellowship)
- Jagiellonian University Medical College (M.D.)
Awards and Certifications
- American Board of Thoracic Surgery
- American Board of Surgery (Diplomat)
- Associate professor, University of Texas MD Anderson Cancer Center
- American College of Surgeons (Fellow)
- Ronald Belsey Esophageal Surgery Club
- Stuber scholarship, University of Rochester Medical Center
- Class president, Jagiellonian University Medical College
Mesothelioma Clinical Trials Under Dr. Boris Sepesi
- A phase I and II clinical trial to evaluate the safety and feasibility of using the neoadjuvant combination of nivolumab and ipilimumab for patients with resectable pleural mesothelioma.
Publications of Dr. Boris Sepesi
- Corsini, E.M. & Sepesi, B. (2020, March 1). Commentary: Salvage Resection For Stage IIIA Lung Cancer in the Era of Immunotherapy. Seminars In Thoracic And Cardiovascular Surgery.
- Shewale, J.B. et al. (2020, February 1). Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. The Annals of Thoracic Surgery.
- Mitchell, K.G. et al. (2020, January 1). Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small Cell Lung Cancer. Clinical Lung Cancer
- Nelson, D.B. et al. (2020, January). Persistent Opioid Use Among the Elderly After Lung Resection: A SEER-Medicare Study. Annals of Thoracic Surgery.